Sign in / Join Now
ETFs & Funds
Cyclacel: Vastly Undervalued Relative To Peers $
Add a reply...
Latest StockTalks »
people get CYCC breaking news and analysis by email alert.
Get email alerts on CYCC »
Cyclacel Pharmaceuticals, Inc.
Get latest price
From other sites
Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia
at TheStreet (Thu, 7:00AM)
Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results
at TheStreet (Nov 14, 2016)
Cyclacel Pharmaceuticals's Preferred Stock Shares Cross 9% Yield Mark
at TheStreet (Nov 8, 2016)
Cyclacel Pharmaceuticals To Release Third Quarter 2016 Financial Results
at TheStreet (Nov 7, 2016)
Cyclacel's CYC065 Demonstrates Promising Activity In MYCN-Addicted Neuroblastoma In Preclinical Data Presented At Childhood Cancer 2016
at TheStreet (Sep 6, 2016)